Order Article Reprints

Fink M, Vittrup AS, Bastholt L, Svane IM, Donia M, Luczak AA, Ruhlmann CH, Guldbrandt LM, Koehler UH, Winther ML, et al. Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. Cancers. 2021; 13(21):5550. https://doi.org/10.3390/cancers13215550

Fink, Morten, Anders Schwartz Vittrup, Lars Bastholt, Inge Marie Svane, Marco Donia, Adam A. Luczak, Christina H. Ruhlmann, Louise Mahncke Guldbrandt, Ulrich Heide Koehler, Mette Lerche Winther, and et al. 2021. "Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study" Cancers 13, no. 21: 5550. https://doi.org/10.3390/cancers13215550

Fink, M., Vittrup, A. S., Bastholt, L., Svane, I. M., Donia, M., Luczak, A. A., Ruhlmann, C. H., Guldbrandt, L. M., Koehler, U. H., Winther, M. L., Ellebaek, E., Haslund, C. A., & Schmidt, H. (2021). Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. Cancers, 13(21), 5550. https://doi.org/10.3390/cancers13215550